A detailed history of Oppenheimer Asset Management Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 37,429 shares of ACAD stock, worth $612,712. This represents 0.01% of its overall portfolio holdings.

Number of Shares
37,429
Previous 29,557 26.63%
Holding current value
$612,712
Previous $480,000 20.0%
% of portfolio
0.01%
Previous 0.01%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$15.14 - $19.14 $119,182 - $150,670
7,872 Added 26.63%
37,429 $576,000
Q2 2024

Aug 08, 2024

BUY
$14.62 - $18.42 $41,550 - $52,349
2,842 Added 10.64%
29,557 $480,000
Q1 2024

May 06, 2024

SELL
$17.79 - $30.86 $131,058 - $227,345
-7,367 Reduced 21.62%
26,715 $493,000
Q4 2023

Feb 13, 2024

SELL
$20.78 - $31.77 $43,866 - $67,066
-2,111 Reduced 5.83%
34,082 $1.07 Million
Q3 2023

Nov 07, 2023

BUY
$20.84 - $33.47 $224,842 - $361,107
10,789 Added 42.47%
36,193 $754,000
Q2 2023

Aug 02, 2023

BUY
$17.8 - $25.65 $151,335 - $218,076
8,502 Added 50.3%
25,404 $608,000
Q1 2023

May 10, 2023

BUY
$16.32 - $20.92 $55,128 - $70,667
3,378 Added 24.98%
16,902 $318,000
Q4 2022

Feb 06, 2023

SELL
$14.2 - $18.63 $2,996 - $3,930
-211 Reduced 1.54%
13,524 $215,000
Q3 2022

Nov 14, 2022

SELL
$14.11 - $18.27 $12,162 - $15,748
-862 Reduced 5.91%
13,735 $225,000
Q2 2022

Aug 08, 2022

SELL
$13.01 - $27.22 $55,162 - $115,412
-4,240 Reduced 22.51%
14,597 $206,000
Q1 2022

May 12, 2022

BUY
$20.94 - $27.5 $30,949 - $40,645
1,478 Added 8.51%
18,837 $456,000
Q4 2021

Feb 02, 2022

SELL
$16.79 - $27.09 $80,239 - $129,463
-4,779 Reduced 21.59%
17,359 $405,000
Q3 2021

Nov 12, 2021

SELL
$15.78 - $24.77 $103,501 - $162,466
-6,559 Reduced 22.86%
22,138 $368,000
Q2 2021

Aug 03, 2021

SELL
$19.4 - $27.42 $1,629 - $2,303
-84 Reduced 0.29%
28,697 $700,000
Q1 2021

May 17, 2021

BUY
$25.02 - $54.99 $100,054 - $219,905
3,999 Added 16.14%
28,781 $743,000
Q4 2020

Feb 11, 2021

BUY
$41.04 - $56.79 $149,016 - $206,204
3,631 Added 17.17%
24,782 $1.33 Million
Q3 2020

Nov 13, 2020

BUY
$36.42 - $57.0 $334,153 - $522,975
9,175 Added 76.61%
21,151 $872,000
Q2 2020

Aug 11, 2020

BUY
$39.26 - $52.73 $164,695 - $221,202
4,195 Added 53.91%
11,976 $580,000
Q1 2020

May 08, 2020

BUY
$31.65 - $46.87 $55,260 - $81,835
1,746 Added 28.93%
7,781 $329,000
Q4 2019

Feb 07, 2020

BUY
$36.21 - $51.4 $27,592 - $39,166
762 Added 14.45%
6,035 $258,000
Q3 2019

Oct 31, 2019

BUY
$22.22 - $44.01 $25,664 - $50,831
1,155 Added 28.05%
5,273 $190,000
Q2 2019

Aug 09, 2019

SELL
$23.32 - $28.12 $42,232 - $50,925
-1,811 Reduced 30.54%
4,118 $110,000
Q1 2019

Apr 24, 2019

BUY
$16.17 - $27.38 $274 - $465
17 Added 0.29%
5,929 $159,000
Q4 2018

Jan 30, 2019

BUY
$14.32 - $22.92 $84,659 - $135,503
5,912 New
5,912 $96,000
Q4 2017

Feb 07, 2018

SELL
$26.84 - $39.14 $22,599 - $32,955
-842 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$29.49 - $38.37 $24,830 - $32,307
842
842 $32,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.65B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Oppenheimer Asset Management Inc. Portfolio

Follow Oppenheimer Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.